Answers are grounded in this paper and cite their sources.
Explores palmitoylation-coexpressed lncRNA impact on HCC prognosis and treatment response, suggesting clinical utility.
Hepatocellular carcinoma (HCC) lacks effective prognostic biomarkers. We explored the role of palmitoylation-coexpressed long non-coding RNAs (lncRNAs) in HCC progression and tumor microenvironment (TME) remodeling. Using TCGA data, we constructed an 8-lncRNA signature (PCLS) via LASSO and multivariate Cox regression. The PCLS robustly stratified HCC patients into risk groups; high-risk patients exhibited worse overall survival and immunosuppressive TME features. Furthermore, PCLS predicted differential responses to immunotherapy and conventional chemotherapeutic agents. The PCLS signature serves as a powerful prognostic tool, reflecting palmitoylation-mediated lncRNA regulation and TME heterogeneity, offering potential to guide personalized immunotherapy and chemotherapy strategies for HCC management.
No takes yet. Share an insight, caveat, or question.
Lv et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: